Herbert Smith Freehills’ Intellectual Property Podcasts – Episode 1: An Introduction to FRAND

The UK Supreme Court is soon expected to hand down its judgment in the appeals of Unwired Planet v Huawei and ZTE v Conversant concerning FRAND, which were heard together. In advance of the decision itself, this podcast provides a reminder of what FRAND is all about (fair, reasonable and non-discriminatory terms required in the licensing of standard essential patents) and what issues are before the Court, as well as some background to the individual disputes. We will publish a further podcast once the Supreme Court has given its judgment. Read more

Data issues in innovation and collaborations

Businesses in every sector are under pressure to innovate to stay ahead of the competition. ‘’Open innovation’’ is a term that has come to describe innovation which extends beyond the traditional R&D department of a business and embraces a broader pool of talent and ideas within the whole business and frequently also extends to an external partnership with a third party collaborator to assist with and accelerate the process. In our second publication Data issues in innovation and collaborations, following on from our Open Innovation: Collaborate To Innovate report, we take a more detailed look at how data frequently plays a central role in the drive towards ‘’open’’ innovation and the significant value attached to it. Data can be used to generate new products or services and revenue streams, to identify efficiencies within an organisation and reduce costs, and to inform strategic decision-making. Read more

RATIFICATION OF THE UPC AGREEMENT IN SIGHT? GERMAN CONSTITUTIONAL DECISION LIKELY EARLY IN 2020

The outcome is still awaited of the constitutional case objecting to a ratification of the UPCA by Germany, which was listed to be decided in 2019.  In a recent interview, Judge Huber of the German Federal Constitutional Court (which is the court due to decide the case) denied that the delay had anything to do with Brexit, rather that other important cases were also waiting to be decided and took precedence. He suggested that the case might be decided in the early part of 2020. Read more

European pharma patent law update

Hear the latest developments in European pharmaceutical patent law from France, Italy and the UK. Now available on demand. Key topics included: The situation of provisional damages in PI proceedings and the consequences in terms of damages of a wrongly awarded PI in France and Italy The implications of the above with respect to involving … Read more

Harnessing the power of diversity in IP

On Thursday 7 November, our London IP team hosted a panel discussion and roundtable session on 'Harnessing the power of diversity in IP'. This was part of an ongoing campaign with World IP Review (WIPR), to celebrate the achievements of influential women in IP and to improve gender diversity in the profession. Read more

Patent and Pharma Update, October 2019

Key recent developments in the United Kingdom and Europe relating to patents and the pharmaceutical sector In this issue we provide updates from the CJEU on SPCs: in one case the CJEU has declined to consider a referral from the UK while in another the Advocate General has issued his opinion on the interpretation of Article 3(a) … Read more

Open Innovation: Getting the IP right in collaborations

In our recent report on our clients’ perspectives on managing innovation in their organisations “Open Innovation: Collaborate To Innovate” we shared our insights into the world of open collaboration assisted by contributions from a wide range of our clients. As part of our analysis we highlighted the main legal considerations that arise in restructuring a collaboration arrangement. In our first publication following on from the report – Getting the IP right in collaborations – we take a more detailed look at some of the principal intellectual property issues and set out practical steps to consider when embarking on collaboration projects. Read more

CJEU refuses UK High Court’s request for preliminary ruling on SPC applications based on third-party MAs, on account of referred question being “hypothetical” (C-239/19 Eli Lilly v Genentech)

On 5 September 2019, the Ninth Chamber of the CJEU refused a request for referral in relation to the interpretation of Article 3(b) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products ('SPC Regulation'). Read more